Search
Results: 11
Decision Tree Trust (DTTrust)-Based Authentication Mechanism to Secure RPL Routing Protocol on Internet of Battlefield Thing (IoBT)
Providing security on the internet of battlefield things (IoBT) is a crucial task because of various factors such as heterogeneous, dynamic, and resource-constrained devices. Besides, authentication is essential, and it ensures...
Published by: IGI Global Scientific Publishing
A structural biology community assessment of AlphaFold2 applications.
Mehmet Akdel, Douglas EV Pires, Eduard Porta Pardo, Jürgen Jänes, Arthur O Zalevsky, Bálint Mészáros, Patrick Bryant, Lydia L Good, Roman A Laskowski, Gabriele Pozzati, Aditi Shenoy, Wensi Zhu, Petras Kundrotas, Victoria Ruiz Serra, Carlos Hm Rodrigues, Alistair S Dunham, David Burke, Neera Borkakoti, Sameer Velankar, Adam Frost, Jérôme Basquin, Kresten Lindorff-Larsen, Alex Bateman, Andrey V Kajava, Alfonso Valencia, Sergey Ovchinnikov, Janani Durairaj, David B Ascher, Janet M Thornton, Norman E Davey, Amelie Stein, Arne Elofsson, Tristan I Croll, Pedro Beltrao
Dec 09, 2022
Most proteins fold into 3D structures that determine how they function and orchestrate the biological processes of the cell. Recent developments in computational methods for protein structure predictions have reached the...
A structural biology community assessment of AlphaFold2 applications.
Mehmet Akdel, Douglas EV Pires, Eduard Porta Pardo, Jürgen Jänes, Arthur O Zalevsky, Bálint Mészáros, Patrick Bryant, Lydia L Good, Roman A Laskowski, Gabriele Pozzati, Aditi Shenoy, Wensi Zhu, Petras Kundrotas, Victoria Ruiz Serra, Carlos Hm Rodrigues, Alistair S Dunham, David Burke, Neera Borkakoti, Sameer Velankar, Adam Frost, Jérôme Basquin, Kresten Lindorff-Larsen, Alex Bateman, Andrey V Kajava, Alfonso Valencia, Sergey Ovchinnikov, Janani Durairaj, David B Ascher, Janet M Thornton, Norman E Davey, Amelie Stein, Arne Elofsson, Tristan I Croll, Pedro Beltrao
Feb 16, 2023
Most proteins fold into 3D structures that determine how they function and orchestrate the biological processes of the cell. Recent developments in computational methods for protein structure predictions have reached the...
The peroxisomal fatty acid transporter ABCD1/PMP-4 is required in the C. elegans hypodermis for axonal maintenance
Andrea Coppa, Sanjib Guha, Stéphane Fourcade, Janani Parameswaran, Montserrat Ruiz, Ann B Moser, Agatha Schlüter, Michael P Murphy, Jose Miguel Lizcano, Antonio Miranda-Vizuete, Esther Dalfó, Aurora Pujol
Feb 18, 2020
Adrenoleukodystrophy is a neurometabolic disorder caused by a defective peroxisomal ABCD1 transporter of very long-chain fatty acids (VLCFAs). Its pathogenesis is incompletely understood. Here we characterize a nematode model of...
Axonal degeneration Hypodermis Lipid Droplets Mitochondria redox imbalance Peroxisomes X-linked adrenoleukodystrophy ATP Binding Cassette Transporter Subfamily D Member 1 ATP-Binding Cassette Transporters Adrenoleukodystrophy Animals Caenorhabditis elegans Fatty Acids Mice Mice Knockout Subcutaneous Tissue
Defining the origin, evolution, and immune composition of SDH-deficient renal cell carcinoma.
Joana B Neves, Kirsty Roberts, Janani Sivakumaran Nguyen, Soha El Sheikh, My-Anh Tran-Dang, Catherine Horsfield, Faiz Mumtaz, Peter Campbell, Hans Stauss, Maxine GB Tran, Thomas Mitchell
Dec 09, 2022
Succinate dehydrogenase (SDH)-deficient renal cell carcinoma represents a rare subtype of hereditary kidney cancer. Clinical diagnosis can be challenging and there is little evidence to guide systemic therapeutic options. We...
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST)
Alasdair PS Munro, Shuo Feng, Leila Janani, Victoria Cornelius, Parvinder K Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L Goodman, Christopher A Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A van der Klaauw, Nasir Kanji, Vincenzo Libri, Martin J Llewelyn, Alastair C McGregor, Mina Maallah, Angela M Minassian, Patrick Moore, Mehmood Mughal, Yama F Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Tanveer Bawa, Dinesh Saralaya, Sunil Sharma, Ray Sheridan, Emma C Thomson, Shirley Todd, Chris Twelves, Robert C Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S Nguyen-Van-Tam, Matthew D Snape, Xinxue Liu, Saul N Faust, COV-BOOST study group
Jun 13, 2022
BACKGROUND: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety...
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK
Xinxue Liu, Alasdair PS Munro, Shuo Feng, Leila Janani, Parvinder K Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Wanwisa Dejnirattisai, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L Goodman, Christopher A Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A van der Klaauw, Jonathan Kwok, Vincenzo Libri, Martin J Llewelyn, Alastair C McGregor, Angela M Minassian, Patrick Moore, Mehmood Mughal, Yama F Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Teona Serafimova, Dinesh Saralaya, Gavin R Screaton, Sunil Sharma, Ray Sheridan, Ann Sturdy, Piyada Supasa, Emma C Thomson, Shirley Todd, Chris Twelves, Robert C Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S Nguyen-Van-Tam, Victoria Cornelius, Matthew D Snape, Saul N Faust, COV-BOOST study group
May 13, 2022
OBJECTIVES: To evaluate the persistence of immunogenicity three months after third dose boosters. METHODS: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster...
COVID-19 vaccine Fractional dose Heterologous boost Homologous boost Immunogenicity Persistence Third dose Ad26COVS1 Adult Aged Aged 80 and over Antibodies Viral BNT162 Vaccine covid-19 COVID-19 Vaccines ChAdOx1 nCoV-19 Humans Immunogenicity Vaccine Immunoglobulin G Middle Aged SARS-CoV-2 United Kingdom Viral Vaccines mRNA Vaccines